The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Valuation Is Forecasted For The Epitranscriptomic Therapies Market By 2030 Starting From Its 2026 Size?
The epitranscriptomic therapies market has expanded substantially in recent years. This market is projected to expand from $1.56 billion in 2025 to reach $1.9 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 21.6%. Historically, this expansion has been driven by several factors, including progress in RNA biology research, an enhanced comprehension of gene regulation mechanisms, the broadening of oncology research programs, the accessibility of advanced sequencing technologies, and a rise in translational medicine initiatives.
The epitranscriptomic therapies market size is poised for significant expansion in the coming years, projected to reach $4.2 billion in 2030 at a compound annual growth rate (CAGR) of 21.9%. This projected growth is fueled by increasing investments in RNA-based therapeutics, a rising demand for targeted cancer treatments, the broadening of personalized medicine approaches, intensified clinical trial activity within epitranscriptomics, and greater regulatory involvement for innovative RNA therapies. Noteworthy trends during this period include the progressive development of epitranscriptomic drug pipelines, a growing utilization of RNA modification profiling tools, the expansion of combination epitranscriptomic therapies, an increasing integration of bioinformatics in therapy design, and a heightened focus on precision medicine applications.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=33108&type=smp
What Major Drivers Are Influencing Demand In The Epitranscriptomic Therapies Market?
The epitranscriptomic therapies market is anticipated to experience growth due to the rising demand for personalized medicine moving forward. This medical approach involves tailoring healthcare decisions, treatments, and interventions to the distinct characteristics of each patient, such as their genetic profile, lifestyle, and environment. The heightened need for personalized medicine is primarily fueled by the increasing prevalence of chronic and complex diseases, as customized treatments can more effectively address individual patient requirements and improve health outcomes. Personalized medicine supports epitranscriptomic therapies by adapting treatments to an individual’s specific RNA modification patterns, thereby enhancing therapeutic effectiveness and reducing the risk of adverse effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients, which was an increase from six in 2022. The newly approved personalized treatments for 2023 also included seven cancer drugs and three for other diseases and conditions. Therefore, the growing demand for personalized medicine is a significant driver for the expansion of the epitranscriptomic therapies market.
Which Segment Categories Define The Epitranscriptomic Therapies Market?
The epitranscriptomic therapies market covered in this report is segmented –
1) By Therapy Type: Small Molecule Inhibitors; Ribonucleic Acid Modifying Enzymes; Antisense Oligonucleotides; Other Therapy Types
2) By Route of Administration: Injectable; Oral; Other Routes Of Administration
3) By Application: Cancer; Neurological Disorders; Metabolic Diseases; Infectious Diseases; Other Applications
4) By End-User: Hospitals; Research Institutes; Pharmaceutical And Biotechnology Companies; Other End-Users
Subsegments:
1) By Small Molecule Inhibitors: Methyltransferase Inhibitors; Demethylase Inhibitors; Reader Protein Inhibitors; Writer Enzyme Inhibitors; Eraser Enzyme Inhibitors
2) By Ribonucleic Acid Modifying Enzymes: Methyltransferase Enzymes; Demethylase Enzymes; Pseudouridine Synthase Enzymes; Adenosine Deaminase Enzymes; Cytidine Deaminase Enzymes
3) By Antisense Oligonucleotides: Gapmer Oligonucleotides; Splice Modulating Oligonucleotides; Translation Blocking Oligonucleotides; Exon Skipping Oligonucleotides; Gene Expression Silencing Oligonucleotides
4) By Other Therapy Types: Ribonucleic Acid Interference Based Therapies; Messenger Ribonucleic Acid Editing Therapies; Epitranscriptomic Vaccine Platforms; Gene Regulation Modulation Therapies; Combination Epitranscriptomic Therapies
What Major Market Trends Are Driving Changes In The Epitranscriptomic Therapies Market?
Leading companies in the epitranscriptomic therapies market are prioritizing the formation of strategic alliances to develop innovative RNA-modifying cancer treatments. These partnerships are collaborative frameworks where organizations pool resources, expertise, or strengths to achieve shared objectives, leading to accelerated growth, reduced operational risks, and enhanced market competitiveness. For example, in January 2026, STORM Therapeutics Ltd., a UK-based biotechnology company, joined forces with Alida Biosciences Inc., a US-based technology company, to advance cancer therapies that target epitranscriptomic mechanisms. This collaboration is centered on integrating AlidaBio’s EpiPlex and EpiScout platforms with STORM’s clinical trials for STC-15, a pioneering METTL3 inhibitor. The partnership seeks to identify and validate m6A RNA modification biomarkers that can predict patient outcomes and refine therapeutic strategies. This combined effort of drug development and advanced RNA profiling represents a significant stride forward in epitranscriptomic cancer therapies.
Which Major Players Dominate The Epitranscriptomic Therapies Market?
Major companies operating in the epitranscriptomic therapies market are AstraZeneca PLC, GSK plc, Moderna Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Arrakis Therapeutics Inc., AIRNA Corporation, CD Genomics, ProQR Therapeutics N.V., Nimbus Therapeutics LLC, Envisagenics Inc., Skyhawk Therapeutics Inc., Avidity Biosciences Inc., STORM Therapeutics Ltd., Omega Therapeutics Inc., Korro Bio Inc., Accent Therapeutics Inc., Alida Biosciences Inc., and O2nix Bio.
Read the full epitranscriptomic therapies market report here:
https://www.thebusinessresearchcompany.com/report/epitranscriptomic-therapies-market-report
Which Regions Are Poised For Strategic Growth In The Epitranscriptomic Therapies Market?
North America was the largest region in the epitranscriptomic therapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the epitranscriptomic therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Epitranscriptomic Therapies Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=33108&type=smp
Browse Through More Reports Similar to the Global Epitranscriptomic Therapies Market 2026, By The Business Research Company
Ecoa Esource And Clinical Trials Market Report 2026
Epilepsy Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/epilepsy-drugs-global-market-report
Genes Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model